Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136060 | 0.88 | HRH3 (0.43) | HRH3CYP2D6BACE1 | |
| SCHEMBL4135788 | 0.87 | HRH3 (0.51) | HRH3CYP2D6BACE1 | |
| SCHEMBL4141225 | 0.85 | HRH3 (0.49) | HRH3CYP2D6BACE1 | |
| SCHEMBL4142009 | 0.85 | HRH3 (0.48) | HRH3CYP2D6BACE1 | |
| SCHEMBL4139873 | 0.84 | NAAA (0.46) | HRH3 | |
| SCHEMBL4131479 | 0.81 | HRH3 (0.40) | HRH3 | |
| SCHEMBL4128192 | 0.81 | HRH3 (0.39) | HRH3 | |
| SCHEMBL4142343 | 0.81 | HRH3 (0.40) | HRH3BACE1 | |
| SCHEMBL4142054 | 0.79 | HRH3 (0.49) | HRH3CHRNA7 | |
| SCHEMBL4129121 | 0.79 | HRH3 (0.39) | HRH3BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HRH3 1/4885CYP2D6 1777/4885GRM2 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.